Clinical trials: Hematological Cancers
Hodgkin's Lymphoma, Lymphoid Leukemia
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate…
- Conditions
- Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT02593123
- Testing
- mycophenolate mofetil, Sargramostim, Filgrastim
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Myeloproliferative Disorders, Leukemia
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00305682
- Testing
- anti-thymocyte globulin, cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic and Lymphoid Cell Neoplasm
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
This phase II trial studies how well a 2-step approach to stem cell transplant works in treating patients with blood cancers. Giving chemotherapy and total body irradiation before a lymphocyte (white blood cell) and stem cell…
- Trial name
- NCT03712878
- Testing
- Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematologic Neoplasms, Burns
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies.
- Trial name
- NCT05549232
- Testing
- Hypoxic Red Blood Cells
- Where
- Norway
- Volunteers
- 22 people
- Sponsor
- Hemanext
Multiple Myeloma, Renal Insufficiency
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
- Trial name
- NCT00721734
- Testing
- Carfilzomib
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematological Malignancies
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients…
- Trial name
- NCT01246206
- Testing
- Tacrolimus and Thymoglobulin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Hematopoetic Myelodysplasia, Leukemia, Myelogenous, Chronic
- Trial name
- NCT01720264
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sherif S. Farag
Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
- Conditions
- Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
- Trial name
- NCT02383927
- Testing
- Tipifarnib
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 63 people
- Sponsor
- Kura Oncology, Inc.
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Chemotherapy-induced Thrombocytopenia
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung…
- Trial name
- NCT03471078
- Testing
- Avatrombopag
- Where
- 55 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Sobi, Inc.
Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma
Ceritinib Rare Indications Study in ALK+ Tumors
This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration…
- Conditions
- Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma
- Trial name
- NCT02465528
- Testing
- Ceritinib (LDK378)
- Where
- 14 sites in Czechia, Denmark and 6 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematological Malignancies, Myelodysplastic Syndrome
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
The goal of this clinical research study is to learn if the combination of rabbit anti-thymocyte globulin (Thymoglobulin®), sirolimus (Rapamune®), and mycophenolate mofetil (Cellcept®) can help to prevent graft versus host…
- Conditions
- Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
- Trial name
- NCT00506948
- Testing
- Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer.
- Trial name
- NCT00824993
- Testing
- Ibandronate, Vitamin Supplements
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01491958
- Testing
- atorvastatin, Tacrolimus, methotrexate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Hematological Malignancies
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent…
- Trial name
- NCT00500578
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center